ROCKVILLE, Md., Oct. 28, 2024 /PRNewswire/ — I-Mab (NASDAQ: IMAB), a US-based, global, biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will participate in one-on-one and small group meetings with investors at the Truist Securities BioPharma Symposium on November 7, 2024.
Event Details
Meeting Date
Thursday, November 7, 2024
Meetings
One-on-one and small group meetings: November 7, 2024
ManagementParticipants
Sean Fu, PhD, MBA, Interim Chief Executive Officer (CEO)
Joe Skelton, Chief Financial Officer (CFO)
Phillip Dennis, MD, PhD, Chief Medical Officer (CMO)
Tyler Ehler, Senior Director, Investor Relations
For more information, please contact your Truist Securities representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.
For more information, please contact:
Tyler EhlerSenior Director, Investor RelationsIR@imabbio.com
This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
